Tag: Injectable diabetes medication

In 2022, prevalent use of GLP-1 receptor agonists like exenatide reached 27.1% among patients with type 2 diabetes and cardiovascular disease [1.7.1]. For those prescribed exenatide, understanding 'What is the difference between Bydureon and Bydureon BCise?' is key, as the delivery devices are vastly different.

Over 30 million adults in the U.S. have type 2 diabetes, a chronic condition requiring careful management of blood sugar. Among the newest and most effective therapies is the M injectable for diabetes, Mounjaro, a once-weekly medication with a novel dual-action mechanism.